Athersys, Inc. Stock Price, News & Analysis

Athersys, Inc. (NASDAQ: ATHX) plans to file its Form 10-Q for the quarter ending September 30, 2022, with the SEC on November 14, 2022. A news release detailing financial results and business highlights will follow on November 15, 2022, accompanied by a conference call at 11:00 a.m. Eastern Time. This rescheduling allows the company to finalize accounting for recently issued equity warrants. Shareholders can participate in the call via webcast and are encouraged to submit questions in advance.

Athersys, Inc. (NASDAQ: ATHX) has priced its public offering of 5,004,545 shares of common stock and warrants for 10,009,090 shares at $1.10 each, totaling approximately $5.5 million before fees. The offering is expected to close around November 10, 2022, pending customary conditions. The funds will be used for general corporate purposes. Alliance Global Partners is the sole placement agent. This offering is made under an effective shelf registration statement filed with the SEC, and further details will be available in the prospectus supplement.

Athersys, Inc. (Nasdaq: ATHX) announced its intention to conduct a public offering of common stock and warrants. The offering's size and terms will depend on market conditions. Proceeds will be utilized for general corporate purposes. A.G.P./Alliance Global Partners is the sole placement agent. The public offering will follow an effective shelf registration statement previously filed with the SEC, and the preliminary prospectus will be available online. This announcement does not constitute an offer to sell or solicitations to buy securities in jurisdictions where it would be unlawful.

Athersys, Inc. (Nasdaq: ATHX) will hold a conference call on November 10, 2022, at 4:30 PM Eastern Time to discuss its third quarter 2022 financial results. Investors are encouraged to listen via the provided webcast link. Additionally, a replay will be available on the company’s website under the investors' section shortly after the call, lasting until November 17, 2022.

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company, announced its participation in two conferences: the 2022 Cell & Gene Meeting on the Mesa from October 11-13, 2022 and the 14^th World Stroke Congress from October 26-29, 2022. Dr. Robert W. Mays will present a corporate overview of MultiStem^® on October 11 at the Cell & Gene Meeting. The company will discuss ongoing clinical studies related to ischemic stroke and other critical care indications. Additionally, Dr. Mays will engage with professionals at the World Stroke Congress.

Athersys, Inc. (NASDAQ: ATHX) will host a business update conference call on October 6, 2022, at 4:00 pm Eastern Time. Key executives, including CEO Dan Camardo and COO Maia Hansen, will discuss the company's achievements following its recent restructuring. Athersys focuses on its MultiStem^® therapy, which aims to promote healing and tissue repair. Participants can register via a webcast link or a call registration link.

Athersys (NASDAQ: ATHX) announced amendments to its warrants agreement, extending the exercise period and allowing the issuance of new warrants to a U.S. institutional investor. This investor previously invested $12 million in Athersys, now committing to participate in future financing. Key amendments include a reduction of the standstill period from 180 days to 150 days and a significant right to participate in future offerings. The company plans to provide updates during a conference call scheduled for the week of October 3.

Athersys, Inc. (NASDAQ: ATHX) announced a 1-for-25 reverse stock split, effective after the market closes on August 26, 2022. This move aims to ensure compliance with Nasdaq's minimum bid price requirement. Post-split, shares will trade on a split-adjusted basis starting August 29, 2022, under the same symbol, ATHX. This decision was approved by stockholders at the annual meeting on July 28, 2022, with the Board determining the final ratio. No fractional shares will be issued; instead, stockholders will receive cash for any fractions.

Athersys, Inc. (NASDAQ: ATHX) has successfully closed a registered direct offering with a U.S. institutional investor, selling 48 million shares and warrants at a total price of $12 million. Each share was priced at $0.25, with warrants exercisable at $0.2554 each over five years. The company plans to use the proceeds for general corporate purposes. Alliance Global Partners served as the sole placement agent for this offering, which is registered under SEC Form S-3.